Small-Molecule Drug Reverses Neural Effects of Concussion
A small molecule called ISRIB that was identified at UCSF can reverse the neuronal and cognitive effects of concussion in mice weeks after an injury occurred, new research found.
University of California San Francisco
Give to UCSFA small molecule called ISRIB that was identified at UCSF can reverse the neuronal and cognitive effects of concussion in mice weeks after an injury occurred, new research found.
Not all senescent cells are harmful “zombies” that should be wiped out to prevent age-related disease. New research from UCSF found that some of them are embedded in young, healthy tissues and promote normal repair from damage.
A new study points to another persistent effect of COVID-19, identified months after infection: reduced exercise capacity.
After a decade of work, scientists at UCSF’s Neuroscape Center have developed a suite of video game interventions that improve key aspects of cognition in aging adults.
A new study shows that fewer Black, Hispanic and Asian patients would qualify for these treatments that may slow Alzheimer’s progression, since cognitive impairment in these groups is more likely to be caused by other forms of dementia that may be unrelated to amyloid plaques.
A newly identified set of molecules alleviated pain in mice while avoiding the sedating affect that limits the use of opiates, according to a new study led by researchers at UC San Francisco.
UCSF has revealed how blood vessel cells develop in the prenatal human brain, paving the way to fully understand the role of these cells in healthy brain development and disease.
Scientists have designed compounds that hit the same key receptor that LSD activates without causing hallucinations. A single dose produced powerful antidepressant and antianxiety effects in mice that lasted up to two weeks.
A mortality prediction model for older adults with dementia may help physicians determine which treatments to provide while facilitating decision-making for patients and their families.
UCSF researchers Adam Staffaroni, PhD, and Adam Boxer, MD, PhD developed models of clinical and biomarker dynamics to determine the temporal sequence of biomarker and clinical changes in f-FTD before disease progression begins.
Researchers have found significant differences between the gut bacteria profiles of multiple sclerosis (MS) patients and healthy individuals, showing new pathways for potential treatment.